Novo Nordisk has launched its Wegovy weight-loss pill in the United States at lower prices. The once-daily pill is the first GLP-1 weight-loss tablet available on the market. It costs significantly less than injectable versions, accelerating competition across the sector. The drug received US approval shortly before Christmas and is now widely available. Cash-paying patients can buy the starting dose for $149 per month. Injectable GLP-1 drugs typically cost around $1,000 monthly. Novo hopes the pill will expand access for millions living with obesity. The launch pressures rivals such as Eli Lilly, which is developing its own obesity pill. Wegovy tablets are available through major pharmacies including CVS and Costco. Novo’s shares rose after the announcement despite intense competition.
Novo Nordisk Launches Wegovy Weight-Loss Pill in US, Intensifying Price War
By OMN AI
